140 related articles for article (PubMed ID: 3933676)
1. Possible mechanism for mianserin induced neutropenia associated with saturable elimination kinetics.
O'Donnell JL; Sharman JR; Begg EJ; Colls BM; Moller PW
Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1375-6. PubMed ID: 3933676
[TBL] [Abstract][Full Text] [Related]
2. Blood dyscrasias and mianserin.
Adams PC; Robinson A; Reid MM; Vishu MC; Livingston M
Postgrad Med J; 1983 Jan; 59(687):31-3. PubMed ID: 6866871
[TBL] [Abstract][Full Text] [Related]
3. Mianserin: a possible cause of neutropenia and agranulocytosis. Adverse Drug Reactions Advisory Committee.
Med J Aust; 1980 Dec; 2(12):673-4. PubMed ID: 7219304
[TBL] [Abstract][Full Text] [Related]
4. Neutropenia following mianserin.
Wilcox JB
N Z Med J; 1982 Jul; 95(712):515. PubMed ID: 6955689
[No Abstract] [Full Text] [Related]
5. Neutropenia and mianserin.
Forgan-Smith J; Leslie P
Med J Aust; 1985 Oct; 143(9):398. PubMed ID: 4058350
[No Abstract] [Full Text] [Related]
6. Agranulocytosis and mianserin.
Edwards IR
N Z Med J; 1985 Feb; 98(772):75-6. PubMed ID: 3856152
[No Abstract] [Full Text] [Related]
7. Neutropenic enterocolitis during mianserin-induced agranulocytosis.
Braye SG; Copplestone JA; Gartell PC
Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1117. PubMed ID: 6812772
[No Abstract] [Full Text] [Related]
8. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I.
Chaplin S
Adverse Drug React Acute Poisoning Rev; 1986; 5(2):97-136. PubMed ID: 3529881
[No Abstract] [Full Text] [Related]
9. Mianserin and agranulocytosis.
Curson DA; Hale AS
Br Med J; 1979 Feb; 1(6160):378-9. PubMed ID: 761018
[TBL] [Abstract][Full Text] [Related]
10. Mianserin induced agranulocytosis presenting as an abscess.
Brumé J; Meehan SE; Bennet RA
Scott Med J; 1983 Oct; 28(4):373-4. PubMed ID: 6648504
[TBL] [Abstract][Full Text] [Related]
11. Mianserin-induced agranulocytosis.
Page CE
Br Med J (Clin Res Ed); 1982 Jun; 284(6333):1912-3. PubMed ID: 6805758
[No Abstract] [Full Text] [Related]
12. Mianserin-induced agranulocytosis.
Br Med J (Clin Res Ed); 1982 Aug; 285(6339):437-8. PubMed ID: 6809113
[No Abstract] [Full Text] [Related]
13. [Agranulocytosis during treatment with mianserin (Tolvon)].
Skallgård F
Ugeskr Laeger; 1981 Nov; 143(46):3057. PubMed ID: 7331004
[No Abstract] [Full Text] [Related]
14. Mianserin and agranulocytosis.
Morgan CA; Donaldson MD
Med J Aust; 1986 Feb; 144(3):165. PubMed ID: 3945209
[No Abstract] [Full Text] [Related]
15. [Agranulocytosis during treatment with mianserin].
Lombrail P; Feuilhade F; Hervé P; Vernant JP; Roudot F
Therapie; 1981; 36(5):593-4. PubMed ID: 7323999
[No Abstract] [Full Text] [Related]
16. Mianserin-induced agranulocytosis.
Br Med J (Clin Res Ed); 1982 Jul; 285(6336):208-9. PubMed ID: 6807414
[No Abstract] [Full Text] [Related]
17. Mianserin.
Edwards IR
N Z Med J; 1985 May; 98(778):350. PubMed ID: 3858725
[No Abstract] [Full Text] [Related]
18. Mianserin and blood dyscrasias.
Clink HM
Br J Clin Pharmacol; 1983; 15 Suppl 2(Suppl 2):291S-293S. PubMed ID: 6824559
[TBL] [Abstract][Full Text] [Related]
19. Mianserin. An example of balancing benefits and risks in therapy.
Mashford ML
Med J Aust; 1984 Sep; 141(5):308-10. PubMed ID: 6433157
[No Abstract] [Full Text] [Related]
20. [The safety of Tolvon].
Hermans RB
Ned Tijdschr Geneeskd; 1983 Nov; 127(48):2203. PubMed ID: 6656907
[No Abstract] [Full Text] [Related]
[Next] [New Search]